Subtopic Deep Dive
Gut Microbiota-Derived Short Chain Fatty Acids
Research Guide
What is Gut Microbiota-Derived Short Chain Fatty Acids?
Gut Microbiota-Derived Short Chain Fatty Acids (SCFAs) are fermentation products like acetate, propionate, and butyrate produced by colonic bacteria from undigested carbohydrates, influencing host energy homeostasis, inflammation, and intestinal barrier function.
Colonic fermentation by microbiota generates SCFAs, which are absorbed and exert systemic effects (Macfarlane & Macfarlane, 2012; 931 citations). These metabolites regulate gut barrier integrity and immune responses (Di Tommaso et al., 2021; 463 citations). Over 10 papers in the provided list link SCFAs to dysbiosis in diseases like Parkinson's and CKD.
Why It Matters
SCFAs from gut microbiota modulate intestinal barrier function, reducing permeability in inflammatory conditions (Di Tommaso et al., 2021). In chronic kidney disease, SCFA alterations contribute to dysbiosis and muscle wasting (Sabatino et al., 2014; Sabatino et al., 2020). Therapeutic diets increasing SCFA production improve outcomes in IBD and sarcopenia (Bischoff et al., 2023; Liu et al., 2021). Plant-based diets elevating SCFAs manage CKD complications (Carrero et al., 2020).
Key Research Challenges
Quantifying SCFA Production Variability
Inter-individual differences in microbiota composition lead to variable SCFA yields from identical diets (Macfarlane & Macfarlane, 2012). Measuring colonic SCFAs in vivo remains technically challenging due to rapid absorption. Liu et al. (2021) highlight gaps in linking dysbiosis to sarcopenia via SCFAs.
Linking SCFAs to Systemic Diseases
Causal pathways from gut SCFAs to conditions like Parkinson's and CKD are unclear despite associations (Hasegawa et al., 2015; Sabatino et al., 2020). Barrier dysfunction amplifies SCFA effects on immunometabolism (Belizário et al., 2018). Clinical translation requires longitudinal studies.
Developing SCFA-Targeted Therapies
Dietary interventions to boost SCFAs face compliance issues in critically ill patients (McClave et al., 2016). GLP-2 modulation interacts with SCFA pathways but lacks specificity (Drucker & Yusta, 2013). ESPEN guidelines note insufficient evidence for IBD nutrition (Bischoff et al., 2023).
Essential Papers
Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient
Stephen A. McClave, Beth Taylor, Robert G. Martindale et al. · 2016 · Journal of Parenteral and Enteral Nutrition · 3.8K citations
This document represents the first collaboration between 2 organizations-the American Society for Parenteral and Enteral Nutrition and the Society of Critical Care Medicine-to describe best practic...
Bacteria, Colonic Fermentation, and Gastrointestinal Health
G.T. Macfarlane, Sandra Macfarlane · 2012 · Journal of AOAC International · 931 citations
Abstract The colonic microbiota plays an important role in human digestive physiology and makes a significant contribution to homeostasis in the large bowel. The microbiome probably comprises thous...
Intestinal Dysbiosis and Lowered Serum Lipopolysaccharide-Binding Protein in Parkinson’s Disease
Satoru Hasegawa, Sae Goto, Hirokazu Tsuji et al. · 2015 · PLoS ONE · 505 citations
The permeability to LPS is likely to be increased without compromising the integrity of intestinal mucosa in PD. The increased intestinal permeability in PD may make the patients susceptible to int...
Intestinal Barrier in Human Health and Disease
Natalia Di Tommaso, Antonio Gasbarrini, Francesca Romana Ponziani · 2021 · International Journal of Environmental Research and Public Health · 463 citations
The intestinal mucosa provides a selective permeable barrier for nutrient absorption and protection from external factors. It consists of epithelial cells, immune cells and their secretions. The gu...
Sarcopenia in chronic kidney disease: what have we learned so far?
Alice Sabatino, Lílian Cuppari, Peter Stenvinkel et al. · 2020 · Journal of Nephrology · 458 citations
Abstract The term sarcopenia was first introduced in 1988 by Irwin Rosenberg to define a condition of muscle loss that occurs in the elderly. Since then, a broader definition comprising not only lo...
Gut Microbiome Dysbiosis and Immunometabolism: New Frontiers for Treatment of Metabolic Diseases
José Ernesto Belizário, Joel Faintuch, Miguel Garay-Malpartida · 2018 · Mediators of Inflammation · 336 citations
Maintenance of healthy human metabolism depends on a symbiotic consortium among bacteria, archaea, viruses, fungi, and host eukaryotic cells throughout the human gastrointestinal tract. Microbial c...
Physiology and Pharmacology of the Enteroendocrine Hormone Glucagon-Like Peptide-2
Daniel J. Drucker, Bernardo Yusta · 2013 · Annual Review of Physiology · 326 citations
Glucagon-like peptide-2 (GLP-2) is a 33-amino-acid proglucagon-derived peptide secreted from enteroendocrine L cells. GLP-2 circulates at low basal levels in the fasting period, and plasma levels r...
Reading Guide
Foundational Papers
Start with Macfarlane & Macfarlane (2012; 931 citations) for core colonic fermentation mechanisms; follow with Drucker & Yusta (2013; 326 citations) for enteroendocrine links and Sabatino et al. (2014; 216 citations) for CKD dysbiosis.
Recent Advances
Study Liu et al. (2021; 302 citations) for gut-muscle axis; Di Tommaso et al. (2021; 463 citations) for barrier function; Bischoff et al. (2023; 281 citations) for IBD guidelines.
Core Methods
Colonic fermentation assays, 16S rRNA sequencing for microbiota, gas chromatography for SCFA quantification, and GLP-2 secretion models (Macfarlane 2012; Hasegawa 2015).
How PapersFlow Helps You Research Gut Microbiota-Derived Short Chain Fatty Acids
Discover & Search
Research Agent uses searchPapers and exaSearch to find SCFA literature like 'Bacteria, Colonic Fermentation, and Gastrointestinal Health' (Macfarlane & Macfarlane, 2012), then citationGraph reveals 931 citing papers on dysbiosis, while findSimilarPapers uncovers links to CKD barrier studies.
Analyze & Verify
Analysis Agent applies readPaperContent to extract SCFA quantification methods from Macfarlane (2012), verifies claims with CoVe chain-of-verification, and runs PythonAnalysis on microbiome datasets for statistical correlations (e.g., pandas correlation of dysbiosis scores and SCFA levels), graded by GRADE for evidence strength in IBD contexts.
Synthesize & Write
Synthesis Agent detects gaps in SCFA-sarcopenia links from Liu (2021), flags contradictions between dysbiosis papers, and uses latexEditText with latexSyncCitations to draft reviews; Writing Agent compiles with latexCompile and exportMermaid for microbiota fermentation pathway diagrams.
Use Cases
"Analyze SCFA levels correlations in CKD dysbiosis datasets from recent papers"
Research Agent → searchPapers('SCFA CKD dysbiosis') → Analysis Agent → readPaperContent(Sabatino 2020) → runPythonAnalysis(pandas correlation on extracted microbiome data) → statistical p-values and plots exported.
"Write LaTeX review on SCFA roles in gut barrier for IBD guidelines"
Synthesis Agent → gap detection across Bischoff 2023 and Di Tommaso 2021 → Writing Agent → latexEditText(structured sections) → latexSyncCitations(10 papers) → latexCompile(PDF) with exportMermaid(SCFA absorption diagram).
"Find code for modeling colonic SCFA fermentation from papers"
Research Agent → paperExtractUrls(Macfarlane 2012) → Code Discovery → paperFindGithubRepo → githubRepoInspect → runnable Python simulator for acetate/propionate ratios.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ SCFA papers: searchPapers → citationGraph → GRADE grading → structured report on fermentation pathways. DeepScan applies 7-step analysis with CoVe checkpoints to verify SCFA-dysbiosis claims in Hasegawa (2015). Theorizer generates hypotheses linking SCFAs to sarcopenia from Liu (2021) and Belizário (2018).
Frequently Asked Questions
What defines gut microbiota-derived SCFAs?
SCFAs are acetate, propionate, and butyrate produced by colonic bacteria fermenting undigested carbohydrates, as detailed in Macfarlane & Macfarlane (2012).
What methods measure SCFAs in research?
Gas chromatography quantifies SCFAs in fecal samples; microbiota profiling via 16S rRNA links composition to yields (Macfarlane & Macfarlane, 2012; Hasegawa et al., 2015).
What are key papers on SCFAs?
Foundational: Macfarlane & Macfarlane (2012; 931 citations) on fermentation; Drucker & Yusta (2013; 326 citations) on GLP-2 interactions. Recent: Liu et al. (2021; 302 citations) on sarcopenia.
What open problems exist in SCFA research?
Causal roles in systemic diseases like CKD and Parkinson's need RCTs; personalized diets boosting SCFAs lack validation (Sabatino et al., 2020; Carrero et al., 2020).
Research Clinical Nutrition and Gastroenterology with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Gut Microbiota-Derived Short Chain Fatty Acids with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.